Evidence map›Paper›PMID 30917313›Full record

ArticleCell reports2019

Dual RNA-Seq of Human Leprosy Lesions Identifies Bacterial Determinants Linked to Host Immune Response.

Dennis J Montoya, Priscila Andrade, Bruno J A Silva, Rosane M B Teles, Feiyang Ma, Bryan Bryson, Saheli Sadanand, Teia Noel, Jing Lu, Euzenir Sarno and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Frontiers in microbiology · 2023
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Using Omics to Study Leprosy, Tuberculosis, and Other Mycobacterial Diseases.Frontiers in cellular and infection microbiology · 2022
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 3 countries.

Dennis J MontoyaDepartment of Molecular, Cell, and Developmental Biology, University of California Los Angeles, Los Angeles, CA, USA.
Priscila AndradeDivision of Dermatology, David Geffen School of Medicine, Los Angeles, CA, USA.
Bruno J A SilvaDivision of Dermatology, David Geffen School of Medicine, Los Angeles, CA, USA.
Rosane M B TelesDivision of Dermatology, David Geffen School of Medicine, Los Angeles, CA, USA.
Feiyang MaDepartment of Molecular, Cell, and Developmental Biology, University of California Los Angeles, Los Angeles, CA, USA.
Bryan BrysonHarvard T.H. Chan School of Public Health, Department of Immunology and Infectious Diseases, Boston, MA, USA.
Saheli SadanandRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Teia NoelDepartment of Molecular, Cell, and Developmental Biology, University of California Los Angeles, Los Angeles, CA, USA.
Jing LuDepartment of Molecular, Cell, and Developmental Biology, University of California Los Angeles, Los Angeles, CA, USA.
Euzenir SarnoDepartment of Mycobacteriosis, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Kristine B ArnvigInstitute for Structural and Molecular Biology, University College London, London WC1E 6BT, UK.
Douglas YoungNational Institute for Medical Research, Mycobacterial Research Division, London NW7 1AA, UK; The Francis Crick Institute, Mill Hill Laboratory, The Ridgeway, Mill Hill, London NW7 1AA, UK.
Ramanuj LahiriHealth Resources and Services Administration (HRSA), National Hansen's Disease Program (NHDP), Baton Rouge, LA, USA.
Diana L WilliamsHealth Resources and Services Administration (HRSA), National Hansen's Disease Program (NHDP), Baton Rouge, LA, USA; Department of Pathobiological Sciences, Louisiana State University (LSU), Baton Rouge, LA, USA.
Sarah FortuneHarvard T.H. Chan School of Public Health, Department of Immunology and Infectious Diseases, Boston, MA, USA.
Barry R BloomHarvard T.H. Chan School of Public Health, Department of Immunology and Infectious Diseases, Boston, MA, USA.
Matteo PellegriniDepartment of Molecular, Cell, and Developmental Biology, University of California Los Angeles, Los Angeles, CA, USA.
Robert L ModlinDivision of Dermatology, David Geffen School of Medicine, Los Angeles, CA, USA. Electronic address: rmodlin@mednet.ucla.edu.
University of California, Los Angeles · USHarvard University · USFundação Oswaldo Cruz · BRHealth Resources and Services Administration · USLouisiana State University · USRagon Institute of MGH, MIT and Harvard · USThe Francis Crick Institute · GBUniversity College London · GB

Funding

UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
Molecular Analysis of the Host Immune Response in LeprosyR01AI022553 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ROBERT L MODLIN · 1989 to 2026
$15.7M
TCR GAMMA/DELTA LYMPHOCYTES IN HUMAN SKIN LESIONSR01AR040312 · NIAMS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MODLIN, ROBERT L · 1990 to 2025
$10.4M
MARC U*STAR Program at the University of California, Los AngelesT34GM008563 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MCEVOY, MEGAN M, POE, GINA R · 1996 to 2023
$9.7M
Vitamin D Metabolism in LeprosyP50AR063020 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MODLIN, ROBERT L · 2012 to 2016
$7.8M
IL-34 regulation of cutaneous immunity by polarizing myeloid cell differentiationK01AR070911 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KELLY-SCUMPIA, KINDRA · 2017 to 2021
$688k
NCATS NIH HHS UL1 TR000124NIAID NIH HHS R01 AI022553NIAMS NIH HHS K01 AR070911NIAMS NIH HHS P50 AR063020NIAMS NIH HHS R01 AR040312NIGMS NIH HHS T34 GM008563
6 · The paper itself

Abstract

To understand how the interaction between an intracellular bacterium and the host immune system contributes to outcome at the site of infection, we studied leprosy, a disease that forms a clinical spectrum, in which progressive infection by the intracellular bacterium Mycobacterium leprae is characterized by the production of type I IFNs and antibody production. Dual RNA-seq on patient lesions identifies two independent molecular measures of M. leprae, each of which correlates with distinct aspects of the host immune response. The fraction of bacterial transcripts, reflecting bacterial burden, correlates with a host type I IFN gene signature, known to inhibit antimicrobial responses. Second, the bacterial mRNA:rRNA ratio, reflecting bacterial viability, links bacterial heat shock proteins with the BAFF-BCMA host antibody response pathway. Our findings provide a platform for the interrogation of host and pathogen transcriptomes at the site of infection, allowing insight into mechanisms of inflammation in human disease.

Indexed as

RNA, BacterialRNA-SeqAdultAntibodies, BacterialB-Cell Activating FactorFemaleHost-Pathogen InteractionsHumansImmunity, HumoralInterferon Type ILeprosyMaleMycobacterium lepraePlasma CellsRNA, MessengerRNA, RibosomalAntibodies, BacterialB-Cell Activating FactorInterferon Type IRNA, BacterialRNA, MessengerRNA, RibosomalTNFSF13B protein, humanbioinformaticscomputational biologyheat shockhost-pathogenhumoralimmunologymicrobiologymycobacteriaplasma cellsequencingsystems immunologytranscriptometranslationaltuberculosis

Identifiers

PMID30917313
PMCPMC6508871
OpenAlexW2952673316

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.